Methods and compositions for imaging amyloid deposits
AssigneeThe Trustees of Columbia University in the City of New York
InventorsSuzanne Lentzsch, Akiva Mintz
Life of this patent
Estimating the term…
Abstract
Methods and diagnostic compositions for detection of amyloid deposits using a chimeric (e.g., mouse-human) antibody or antigen-binding fragment thereof linked to a detectable label are disclosed.
Claims31
An in vivo method of detecting the presence, location and/or quantity of cardiac-derived AL amyloid deposits in a patient suspected of having AL amyloid deposits comprising:
- administering to the patient a chimeric antibody having a detectable label linked thereto, the antibody comprising:
- a variable heavy chain (VH) comprising SEQ ID NO:
- 48;
- and a variable light chain (VK) comprising SEQ ID NO:
- 47;
- and
- detecting the presence, location, and/or quantity of cardiac-derived AL amyloid deposits by detecting the detectable label bound to the cardiac-derived AL amyloid deposits by diagnostic imaging,
- wherein the antibody is detectable at least at 7 days post administration, thereby detecting the presence, location and/or quantity of cardiac-derived AL amyloid deposits.
A composition for detecting the presence, location, and/or quantity of cardiac-derived AL amyloid deposits in a subject comprising a chimeric antibody having a detectable label linked thereto, the antibody comprising:
- a variable heavy chain (VH) comprising SEQ ID NO:
- 48;
- and a variable light chain (VK) comprising SEQ ID NO:
- 47, wherein the antibody is detectable for at least 7 days.
Dependencies are inferred from the claim text.